Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus PANIXINE DISPERDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus PANIXINE DISPERDOSE.
CEFIZOX vs PANIXINE DISPERDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic